Proove Biosciences, which sold dubious DNA tests to predict addiction risk, sells off assets as CEO departs amid criminal probe
By Charles Piller,
STAT
| 08. 31. 2017
Proove Biosciences, a formerly high-flying genetic testing firm whose science and business practices have been challenged by experts and former employees, has been placed into court-ordered receivership for “restructuring and asset sale,” according to the company’s founder and former CEO.
Proove’s founder, Brian Meshkin, said in an interview on Thursday that he no longer works at Proove, which rang up $28 million in revenue last year. Meshkin blamed the company’s fall on investigative articles published by STAT last December and February. Those articles quoted experts who expressed deep doubts about the company’s scientific claims that it could predict a patient’s likelihood of becoming addicted to opioids. “Hogwash” was the assessment of Dr. Mary Jeanne Kreek, a leading researcher on genetic links to addiction at Rockefeller University.
STAT’s investigations also described business practices — including coercing patients to take unnecessary genetic tests — that former Proove employees and outside experts described as unethical and possibly illegal.
In June, agents from the FBI and Department of Health and Human Services agents raided Proove’s offices in Irvine, Calif. to collect truckloads of documents...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
